Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
Sign Up to like & getrecommendations! Published in 2019 at "Pulmonary Circulation"
DOI: 10.1177/2045894019862167
Abstract: Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH). However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, side effects, or sociocultural… read more here.
Keywords: prostacyclin; parental prostacyclin; transition; pulmonary arterial ... See more keywords